Health-tech startup Thrixen bags US$7 million from 22Health Ventures, Aldevron co-founder
Funds will help advance the development of its diagnostic technology platform, which has the potential to perform multiplex diagnostic tests at the point of care for the first time, says Singapore-based firm
HEALTH-TECH startup Thrixen has raised US$7 million in a round co-led by new investors 22Health Ventures, an early-stage health-tech investment firm, and John Ballantyne, co-founder of leading biotech player Aldevron. Thrixen said it will use the funds to advance the development of its diagnostic technology platform, which has the potential to perform multiplex diagnostic tests at the point of care for the first time.
